Epigenetics

Epigenetics

Global Epigenetics Market to Reach US$3.9 Billion by 2030

The global market for Epigenetics estimated at US$1.6 Billion in the year 2023, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2023-2030. Epigenetics Kits, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Epigenetics Reagents segment is estimated at 13.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$449.9 Million While China is Forecast to Grow at 12.5% CAGR

The Epigenetics market in the U.S. is estimated at US$449.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$598.9 Million by the year 2030 trailing a CAGR of 12.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.9% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Epigenetics - Key Trends and Drivers

Epigenetics is a rapidly evolving field of biology that studies changes in gene expression that do not involve alterations to the underlying DNA sequence. These changes are brought about by epigenetic mechanisms such as DNA methylation, histone modification, and non-coding RNA-associated gene silencing. DNA methylation involves the addition of a methyl group to DNA, typically acting to suppress gene transcription. Histone modifications, including methylation, acetylation, phosphorylation, and ubiquitination, influence gene expression by altering chromatin structure, thereby making DNA more or less accessible to transcriptional machinery. Non-coding RNAs, such as microRNAs and long non-coding RNAs, regulate gene expression at the post-transcriptional level. Epigenetics plays a crucial role in numerous biological processes, including development, differentiation, and adaptation to environmental changes. It also has significant implications for understanding complex diseases such as cancer, neurological disorders, and autoimmune diseases.

Technological advancements have significantly propelled the field of epigenetics, enabling researchers to explore epigenetic modifications with unprecedented precision and depth. High-throughput sequencing technologies, such as next-generation sequencing (NGS), have revolutionized the ability to map epigenetic changes across the genome. Techniques like chromatin immunoprecipitation sequencing (ChIP-seq) and bisulfite sequencing allow scientists to investigate histone modifications and DNA methylation patterns, respectively, on a genome-wide scale. Additionally, CRISPR-based tools have been adapted for epigenome editing, enabling targeted modifications of epigenetic marks to study their functional consequences. Single-cell epigenomics is another emerging area, providing insights into the heterogeneity of epigenetic regulation at the level of individual cells. These technological advancements are not only deepening our understanding of epigenetic mechanisms but also paving the way for novel therapeutic approaches in precision medicine, such as epigenetic drugs that can reverse aberrant epigenetic modifications in disease.

The growth in the epigenetics market is driven by several factors, including increasing investments in research and development, the rising prevalence of complex diseases, and advancements in technology. Pharmaceutical and biotechnology companies are investing heavily in epigenetics research to discover new drug targets and develop epigenetic therapies. The rising incidence of cancers, neurological disorders, and autoimmune diseases, which are often associated with epigenetic dysregulation, is fueling demand for epigenetic research and diagnostics. Advancements in high-throughput technologies and bioinformatics tools are making it easier and more cost-effective to study epigenetic modifications, thus accelerating research efforts. Additionally, the integration of epigenetics with other omics technologies, such as genomics, transcriptomics, and proteomics, is providing comprehensive insights into disease mechanisms and identifying novel biomarkers for early diagnosis and personalized treatment. The increasing collaboration between academic institutions, research organizations, and industry players is also fostering innovation and expanding the application of epigenetic discoveries in clinical settings. Overall, the epigenetics market is poised for significant growth, driven by technological advancements, rising disease prevalence, and substantial research investments.

Select Competitors (Total 72 Featured) -

• Abcam PLC
• Active Motif, Inc.
• CellCentric
• Diagenode SA
• Eisai Co., Ltd.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• MilliporeSigma
• Novartis International AG
• Oncolys BioPharma Inc.
• QIAGEN GmbH
• Syndax Pharmaceuticals, Inc.
• Thermo Fisher Scientific, Inc.
• Valirx Plc
• Zymo Research Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.